metoprolol has been researched along with Behavior Disorders in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 9.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 5.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 5.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "Propranolol is a widely used beta-blocker mainly prescribed for the treatment of hypertension and other cardiac conditions." | 1.62 | Propranolol and metoprolol: Two comparable drugs with very different post-mortem toxicological profiles. ( Kaukonen, M; Kriikku, P; Ojanperä, I; Pelkonen, S, 2021) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 1.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kriikku, P | 1 |
| Pelkonen, S | 1 |
| Kaukonen, M | 1 |
| Ojanperä, I | 1 |
| Huang, J | 1 |
| Zhang, R | 1 |
| Liu, X | 1 |
| Meng, Y | 1 |
| Paulzen, M | 1 |
| Haen, E | 1 |
| Gründer, G | 1 |
| Lammertz, SE | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Walther, S | 1 |
| Schoretsanitis, G | 1 |
| Johnson, JM | 1 |
1 review available for metoprolol and Behavior Disorders
| Article | Year |
|---|---|
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
2 trials available for metoprolol and Behavior Disorders
| Article | Year |
|---|---|
Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Chronic Disease; Exercise Tolerance; Female; Hear | 2018 |
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
2 other studies available for metoprolol and Behavior Disorders
| Article | Year |
|---|---|
Propranolol and metoprolol: Two comparable drugs with very different post-mortem toxicological profiles.
Topics: Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Cardiovascular Diseas | 2021 |
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antipsychotic Agent | 2016 |